Payment overview · 2025
General Payments
$1,065.21
46 reported records · 22 companies
Healthcare provider profile · identity verified
Jennifer E Lawrence, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · VALDOSTA, GA · NPI 1396827457
Verified facts
What the public records show
CMS Open Payments records show Jennifer E Lawrence, M.D. received $1,065.21 in general payments during 2025 across 46 reported records.
Corcept Therapeutics accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Tirosint.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Jardiance by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tirosint as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Tirosint by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $349.08 | 32.8% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $117.40 | 11.0% | 6 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $60.57 | 5.7% | 4 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $59.28 | 5.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $50.15 | 4.7% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $41.55 | 3.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.11 | 3.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.99 | 3.4% | 2 | 2025 |
| CONMED Corporation | Unresolved — no canonical attribution shown | $31.35 | 2.9% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $27.84 | 2.6% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $26.37 | 2.5% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $25.84 | 2.4% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $22.96 | 2.2% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $22.79 | 2.1% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $20.70 | 1.9% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $20.52 | 1.9% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $20.35 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.21 | 1.9% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $18.98 | 1.8% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $18.24 | 1.7% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.02 | 1.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.91 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $784.83 | 40 |
| Education | $280.38 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $349.08 | 11 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $74.64 | 4 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $60.57 | 4 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $59.28 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $50.15 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $42.76 | 2 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $41.55 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.11 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.11 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $35.99 | 2 | 2025 |
Source payment records
|
|||||
| CONMED BILIARY Normalized: conmed biliary |
Device | CONMED Corporation | $31.35 | 1 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $25.84 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| MYALEPT Normalized: myalept |
Drug | Chiesi USA, Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 166 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 226 | exact normalized | Medicare Part D |
| Tirosint tirosint |
2025 | Tirosint | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
166 | 40 |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Tirosint open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Tirosint · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
226 | 60 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 636 | 216 |
| Synthroid | Levothyroxine Sodium | 319 | 105 |
| Ozempic | Semaglutide | 226 | 60 |
| Jardiance | Empagliflozin | 166 | 40 |
| Metformin Hcl Er | Metformin Hcl | 165 | 54 |
| Pioglitazone Hcl | Pioglitazone Hcl | 146 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 42 |
| Methimazole | Methimazole | 140 | 65 |
| Losartan Potassium | Losartan Potassium | 138 | 35 |
| Mounjaro | Tirzepatide | 126 | 37 |
| Atorvastatin Calcium | Atorvastatin Calcium | 112 | 40 |
| Farxiga | Dapagliflozin Propanediol | 99 | 27 |
| Trulicity | Dulaglutide | 95 | 36 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 89 | 16 |
| Hydrocortisone | Hydrocortisone | 81 | 27 |
| Nateglinide | Nateglinide | 81 | 26 |
| Lisinopril | Lisinopril | 74 | 32 |
| Potassium Chloride | Potassium Chloride | 64 | 20 |
| Metformin Hcl | Metformin Hcl | 61 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 49 | 18 |
| Spironolactone | Spironolactone | 48 | 17 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 45 | 17 |
| Tradjenta | Linagliptin | 44 | 15 |
| Calcitriol | Calcitriol | 43 | 15 |
| Cinacalcet Hcl | Cinacalcet Hcl | 42 | 17 |
| Novolog Flexpen | Insulin Aspart | 40 | 15 |
| Furosemide | Furosemide | 39 | 12 |
| Humalog | Insulin Lispro | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 35 | 20 |
| Sertraline Hcl | Sertraline Hcl | 33 | 15 |
| Cabergoline | Cabergoline | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 19 |
| Ezetimibe | Ezetimibe | 29 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Dexamethasone | Dexamethasone | 27 | 25 |
| Famotidine | Famotidine | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 27 | 11 |
| Novolog | Insulin Aspart | 27 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 26 | 13 |
| Insulin Lispro | Insulin Lispro | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | 13 |
| Tirosint | Levothyroxine Sodium | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | 11 |
| Desmopressin Acetate | Desmopressin Acetate | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Forteo | Teriparatide | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Gabapentin | Gabapentin | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,065.21 · 46 records | Corcept Therapeutics | ACTHAR, Bimzelx, CONMED BILIARY, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE, Flector, JARDIANCE, Korlym, LUPKYNIS, Licart, MYALEPT, Omnipod, Ozempic, PURIFIED CORTROPHIN GEL, QUTENZA, Rybelsus, TEPEZZA, TONMYA, TWIIST, Tirosint, UNITHROID, XELJANZ, XYOSTED, Yorvipath, t:slim X2 Insulin Pump with Control-IQ | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error